ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma

Oncogenesis

Volumn 3, Issue , 2014, Pages

  Belani, R ^a   Oliveira, G ^b   Erikson, G A ^b   Ra, S ^c   Schechter, M S ^d   Lee, J K ^b   Shipman, W J ^b   Haaser, S M ^b   Torkamani, A ^b  

^a San Diego Association of Governments   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c San Diego Pathologists Medical Group Inc   (United States)

^d Imaging Healthcare Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; DNA METHYLTRANSFERASE 3A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CHROMATIN BINDING POLYCOMB GROUP PROTEIN ASXL1; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; EPIDERMAL GROWTH FACTOR RECEPTOR; METABOTROPIC RECEPTOR 5; POLYCOMB GROUP PROTEIN;

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; EXOME; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION; THYMOMA; ACUTE MYELOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; ASIAN; B3 THYMOMA; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; COPY NUMBER VARIATION; COUGHING; CYTOGENETICS; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME ANALYSIS; IMAGE GUIDED BIOPSY; INDEL MUTATION; KIDNEY TUMOR; LOBECTOMY; MEDIASTINUM MASS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR BIOPSY; TUMOR DIAGNOSIS; TUMOR INVASION; ZYGOSITY;

FELIDAE;

EID: 84904811805     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.25     Document Type: Article

References (38)

1. Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol 1999; 17: 2280-2289. (Pubitemid 29318862)
2. Rosai J, Sobin LH. Histological Typing of Tumours of the Thymus. Springer: Berlin; New York, 1999, pp 65.
3. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-2492. (Pubitemid 12228012)
4. Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007; 2: 73-78. (Pubitemid 47163933)
5. Loehrer Sr. PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group. Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12: 1164-1168. (Pubitemid 24173929)
6. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991; 68: 30-33.
7. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011; 29: 4820-4827.
8. Yagi K, Hirata T, Fukuse T, Yokomise H, Inui K, Ike O et al. Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded. Ann Thorac Surg 1996; 61: 521-524.
9. Akaogi E, Ohara K, Mitsui K, Onizuka M, Ishikawa S, Mitsui T et al. Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels. J Surg Oncol 1996; 63: 17-22. (Pubitemid 26353296)
10. Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008; 62: 316-320.
11. Rajan A, Giaccone G. Targeted therapy for advanced thymic tumors. J Thorac Oncol 2010; 5(10 Suppl 4): S361-S364.
12. Kelly RJ. Thymoma versus thymic carcinoma: differences in biology impacting treatment. J Natl Compr Cancer Network 2013; 11: 577-583.
13. Zettl A, Strobel P, Wagner K, Katzenberger T, Ott G, Rosenwald A et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000; 157: 257-266. (Pubitemid 30642585)
14. Inoue M, Marx A, Zettl A, Strobel P, Muller-Hermelink HK, Starostik P. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 2002; 161: 1507-1513.
15. Petrini I, Rajan A, Pham T, Voeller D, Davis S, Gao J et al. Whole genome and transcriptome sequencing of a B3 thymoma. PLoS ONE 2013; 8: e60572.
16. Okano M, Bell DW, Haber DA, Li E. DN A methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-257. (Pubitemid 29519904)
17. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
18. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183. (Pubitemid 38337497)
19. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007; 449: 248-251. (Pubitemid 47402375)
20. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med 2013; 368: 2059-2074.
21. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. New Engl J Med 2010; 363: 2424-2433.
22. Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119: 559-568.
23. Holz-Schietinger C, Matje DM, Reich NO. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem 2012; 287: 30941-30951.
24. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22: 180-193.
25. Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest 2013; 123: 4627-4640.
26. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comblike 1 (ASXL1) mutations. Blood 2010; 116: 4086-4094.
27. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013; 27: 82-91.
28. Pearson JC, Lemons D, McGinnis W. Modulating Hox gene functions during animal body patterning. Nat Rev Genet 2005; 6: 893-904. (Pubitemid 41782157)
29. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109: 431-448. (Pubitemid 46105936)
30. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013; 122: 4086-4089.
31. Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. Leukemogenic transformation by HOXA cluster genes. Blood 2010; 115: 2910-2918.
32. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
33. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
34. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65.
35. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012; 337: 64-69.
36. Zeitouni B, Boeva V, Janoueix-Lerosey I, Loeillet S, Legoix-ne P, Nicolas A et al. SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics 2010; 26: 1895-1896.
37. Zhang H, Meltzer P, Davis S. RCircos: an R package for Circos 2D track plots. BMC Bioinformatics 2013; 14: 244.
38. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.